Previous researches on the association between proton pump inhibitors (PPIs) use and the treatment and prevention of COVID-19 has generated inconsistent findings. Therefore, this meta-analysis was conducted to clarify the outcome in patients who take PPIs. Eight articles with more than 268,683 subjects were included. PPI use was not associated with increased or decreased risk of COVID-19 infection (OR:3.16, 95% CI=0.74-13.43, P=0.12) or mortality risk of COVID-19 patients (OR=1.91, 95% CI=0.86-4.24, P=0.11). While it can add risk of severe disease (OR=1.54, 95% CI=1.20-1.99, P<0.001;) and secondary infection (OR=4.33, 95% CI=2.57-7.29). In summary, PPI use is not associated with an increased risk of infection and may not change the mortality risk of COVID-19, but appeared to be associated with an increased risk of progression to severe disease and secondary infection. However, more original studies to further clarify the relationship between PPI and COVID-19 are still urgently needed.

先前关于质子泵抑制剂 (PPI) 使用与 COVID-19 治疗和预防之间关系的研究产生了不一致的发现。因此，进行这项荟萃分析是为了阐明服用 PPI 的患者的结果。包含超过 268,683 名受试者的 8 篇文章。PPI 的使用与 COVID-19 感染风险的增加或降低（OR：3.16，95% CI=0.74-13.43，P =0.12）或 COVID-19 患者的死亡风险（OR=1.91，95% CI=0.86）无关-4.24，P = 0.11）。虽然它会增加患严重疾病的风险（OR=1.54, 95% CI=1.20-1.99, P<0.001;) 和继发感染 (OR=4.33, 95% CI=2.57-7.29)。总之，PPI 的使用与感染风险增加无关，也可能不会改变 COVID-19 的死亡风险，但似乎与进展为严重疾病和继发感染的风险增加有关。然而，仍然迫切需要更多的原创研究来进一步阐明 PPI 和 COVID-19 之间的关系。